p21WAF-1/Cip-1 gene therapy as an adjunct to glaucoma filtration surgery.
Glaucoma is a blinding eye disease characterized by elevated intraocular pressure (IOP). Glaucoma filtration surgery (GFS) is designed to reduce IOP, but wound healing responses to the procedure can result in surgical failure. Anti-metabolites used in conjunction with GFS are commonly employed to control the wound healing response, but have unwanted side effects. This review describes the therapeutic potential of ocular gene therapy using an adenovirus vector containing the human p21WAF-1/Cip-1 gene (rAd-p21) to control unwanted wound healing post-GFS. Here, we summarize encouraging preclinical data in relevant models, and propose rAd-p21 gene therapy as an alternative to the currently used methods of wound healing modulation.
Atencio
Isabella A
IA
Canji Inc, 3525 John Hopkins Court, San Diego, CA 92121, USA.
Chen
Zoe
Z
Nguyen
Quang H
QH
Faha
Barbara
B
Maneval
Daniel C
DC
D000818:Animals; D018797:Cell Cycle Proteins / Q000235:genetics* / Q000627:therapeutic use*; D050759:Cyclin-Dependent Kinase Inhibitor p21; D015316:Genetic Therapy / Q000379:methods*; D020327:Glaucoma Drainage Implants / Q000009:adverse effects; D006801:Humans
C493956:CDKN1A protein, human; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21